🚀 VC round data is live in beta, check it out!
Celltrion Pharm Valuation Multiples
Discover revenue and EBITDA valuation multiples for Celltrion Pharm and similar public comparables like Tsumura, Hualan Biological Vaccine, Granules India, Intellia Therapeutics and more.
Celltrion Pharm Overview
About Celltrion Pharm
Celltrion Pharm Inc is active in the Korean healthcare sector. Its core business includes the manufacture and sale of pharmaceuticals such as heptatonic, analgesics, antipyretics, anti-inflammatory drugs, antihistamines, respiratory apparatus drugs and antibiotics.
Founded
1976
HQ
Employees
N/A
Website
Sectors
Financials (FY)
EV
$2B
Celltrion Pharm Financials
Celltrion Pharm reported last fiscal year revenue of $363M and EBITDA of $53M.
In the same fiscal year, Celltrion Pharm generated $111M in gross profit, $53M in EBITDA, and $26M in net income.
Celltrion Pharm P&L
In the most recent fiscal year, Celltrion Pharm reported revenue of $363M and EBITDA of $53M.
Celltrion Pharm expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $363M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $111M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 31% | XXX | XXX | XXX |
| EBITDA | — | XXX | $53M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 15% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | 10% | XXX | XXX | XXX |
| Net Profit | — | XXX | $26M | XXX | XXX | XXX |
| Net Margin | — | XXX | 7% | XXX | XXX | XXX |
| Net Debt | — | — | $62M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Celltrion Pharm Stock Performance
Celltrion Pharm has current market cap of $2B, and enterprise value of $2B.
Market Cap Evolution
Celltrion Pharm's stock price is $39.58.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $2B | -0.1% | XXX | XXX | XXX | $0.59 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialCelltrion Pharm Valuation Multiples
Celltrion Pharm trades at 4.9x EV/Revenue multiple, and 33.5x EV/EBITDA.
Celltrion Pharm Financial Valuation Multiples
As of April 18, 2026, Celltrion Pharm has market cap of $2B and EV of $2B.
Equity research analysts estimate Celltrion Pharm's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Celltrion Pharm has a P/E ratio of 66.9x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 4.9x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 33.5x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | 47.0x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 16.1x | XXX | XXX | XXX |
| P/E | — | XXX | 66.9x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 38.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Celltrion Pharm Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Celltrion Pharm Margins & Growth Rates
Celltrion Pharm's revenue in the last fiscal year grew by 12%.
Celltrion Pharm Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 12% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 15% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 37% | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 6% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 1% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 4% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 20% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Celltrion Pharm Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Celltrion Pharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Tsumura | XXX | XXX | XXX | XXX | XXX | XXX |
| Hualan Biological Vaccine | XXX | XXX | XXX | XXX | XXX | XXX |
| Granules India | XXX | XXX | XXX | XXX | XXX | XXX |
| Intellia Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Nuvation Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Celltrion Pharm M&A Activity
Celltrion Pharm acquired XXX companies to date.
Last acquisition by Celltrion Pharm was on XXXXXXXX, XXXXX. Celltrion Pharm acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Celltrion Pharm
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialCelltrion Pharm Investment Activity
Celltrion Pharm invested in XXX companies to date.
Celltrion Pharm made its latest investment on XXXXXXXX, XXXXX. Celltrion Pharm invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Celltrion Pharm
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Celltrion Pharm
| When was Celltrion Pharm founded? | Celltrion Pharm was founded in 1976. |
| Where is Celltrion Pharm headquartered? | Celltrion Pharm is headquartered in South Korea. |
| Is Celltrion Pharm publicly listed? | Yes, Celltrion Pharm is a public company listed on Korea Exchange. |
| What is the stock symbol of Celltrion Pharm? | Celltrion Pharm trades under 068760 ticker. |
| When did Celltrion Pharm go public? | Celltrion Pharm went public in 2006. |
| Who are competitors of Celltrion Pharm? | Celltrion Pharm main competitors are Tsumura, Hualan Biological Vaccine, Granules India, Intellia Therapeutics. |
| What is the current market cap of Celltrion Pharm? | Celltrion Pharm's current market cap is $2B. |
| What is the current revenue of Celltrion Pharm? | Celltrion Pharm's last fiscal year revenue is $363M. |
| What is the current EV/Revenue multiple of Celltrion Pharm? | Current revenue multiple of Celltrion Pharm is 4.9x. |
| Is Celltrion Pharm profitable? | No, Celltrion Pharm is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.